Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02399813 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
A Phase 2 study, sponsored by Advaxis.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02399813: Completed Phase 2 study, sponsored by Advaxis.
NCT02399813 is a Phase 2 study that has completed, run by Advaxis. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02399813, a Phase 2 study, has completed, sponsored by Advaxis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma (SCCA) of the anorectal canal that have received at least 1 regimen for the treatment of advanced disease.
Interventions
- DRUG Axalimogene filolisbac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-06-02 |
| Est. Completion | 2019-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02399813
The ClinicalTrials.gov registry entry for NCT02399813 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advaxis, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Axalimogene filolisbac is the first listed.
NCT02399813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02399813 about?
NCT02399813 is a clinical study titled "A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal". This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma (SCCA) of the anorectal canal that have received at least 1 regimen for the ...
What is the current status of trial NCT02399813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2016-06-02. Estimated completion is 2019-01-03.
What interventions are being tested in trial NCT02399813?
The interventions under investigation include: Axalimogene filolisbac (DRUG).
Who is sponsoring clinical trial NCT02399813?
This trial is sponsored by Advaxis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.